Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Imagion Biosystems Secures AU$3.75M
Business capital raise

Imagion Biosystems Secures AU$3.75M

Analysis based on 6 articles · First reported Jun 25, 2026 · Last updated Jun 30, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The capital raise for Imagion Biosystems is expected to positively impact its stock price and investor confidence, as it secures funding for a crucial Phase 2 clinical trial. This advancement in medical imaging technology could also have broader implications for the biotechnology and medical device industries by offering more precise cancer detection methods.

biotechnology medical devices
Event Summary

Imagion Biosystems, a clinical-stage imaging company, has successfully secured AU$3.75 million (US$2.59 million) in new capital. This funding follows the United States — Food and Drug Administration's clearance of the company's Investigational New Drug (IND) application for a Phase 2 clinical trial of its MagSense imaging agent, designed for HER2-positive breast cancer detection. The capital raise, led by CPS Capital Group, will enable Imagion Biosystems to commence the clinical trial and advance its molecular MRI imaging technology, which aims to improve cancer detection specificity using targeted magnetic nanoparticles. Executive Chairman Robert Proulx highlighted the strong investor demand as a testament to the company's technical and organizational achievements.

Key Actions
100 Imagion Biosystems secured commitments
80 United States — Food and Drug Administration cleared application Imagion Biosystems
70 CPS Capital Group led capital raise Imagion Biosystems
Entities Involved
stock
Imagion Biosystems
Imagion Biosystems secured AU$3.75 million in new capital, which will fund the commencement of a Phase 2 clinical trial for its MagSense imaging agent in HER2-positive breast cancer. This funding is crucial for advancing its molecular MRI technology.
Importance 100.0 Sentiment 75.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration cleared Imagion Biosystems' IND application for a Phase 2 clinical trial, a key milestone that enabled the company to secure new capital.
Importance 60.0 Sentiment 0.0
priv
CPS Capital Group
CPS Capital Group led the capital raise for Imagion Biosystems through a two-tranche placement, demonstrating investor confidence in the company's technology.
Importance 50.0 Sentiment 0.0
per
Robert Proulx
Robert Proulx, Executive Chairman of Imagion Biosystems, expressed satisfaction with the strong investor demand following the FDA clearance, highlighting the significance of the funding for advancing MagSense technology.
Importance 30.0 Sentiment 0.0
curr
Australia — Australian dollar
The capital raise was denominated in Australia — Australian dollars, with AU$3.75 million secured.
Importance 10.0 Sentiment 0.0
cnt
United States
The Australia — Australian dollar amount of the capital raise was also reported in United Statess, approximately US$2.59 million.
Importance 10.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.